Aurinia Pharmaceuticals
AUPH
125 hedge funds and large institutions have $880M invested in Aurinia Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 40 increasing their positions, 26 reducing their positions, and 20 closing their positions.
65% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 20
54% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 26
23% more call options, than puts
Call options by funds: $34.3M | Put options by funds: $28M
9% more funds holding
Funds holding: 115 → 125 (+10)
8.33% more ownership
Funds ownership: 45.7% → 54.03% (+8.3%)
11% less capital invested
Capital invested by funds: $992M → $880M (-$111M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$87.2M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$30.4M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$28.5M |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$19M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$18.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$27.1M |
| 2 |
O
OrbiMed
New York
|
-$17.8M |
| 3 |
PA
Perceptive Advisors
New York
|
-$14.5M |
| 4 |
CLCM
Crawford Lake Capital Management
Lakewood,
New Jersey
|
-$7.25M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$6.33M |
AUPH Hedge Fund Activity: Q1 2020 in Review
125 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q1 2020, worth a combined $880M — down 11% from $992M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new AUPH positions and 20 closed out — a net gain of 13 holders — while 40 added to existing stakes and 26 trimmed.
The largest buyer was HealthCor Management, adding an estimated $87.2M. The largest seller was Millennium Management, cutting an estimated $27.1M.
- 125 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q1 2020, up from 115 in Q4 2019.
- Funds reported $880M of Aurinia Pharmaceuticals stock for Q1 2020, down 11% quarter-over-quarter.
- 33 funds opened new Aurinia Pharmaceuticals positions in Q1 2020 and 20 closed out, a net change of +13 holders.
- The largest Aurinia Pharmaceuticals buyer in Q1 2020 was HealthCor Management, an estimated $87.2M added.
- The largest Aurinia Pharmaceuticals seller in Q1 2020 was Millennium Management, an estimated $27.1M sold.
Based on aggregated 13F filings for Q1 2020.